Anti-Aging
Skin and healthy-aging options are discussed case by case, with evidence that varies substantially by product and intended use.
Consultation pathways
Options in this category may involve off-label or compounded use. They are reviewed case by case with clear disclosure that evidence quality varies and that not every product has large human outcome data.
Topical Rapamycin
TopicalCompounded / individualizedA compounded topical sirolimus formulation discussed for skin-aging concerns at a provider's discretion. This off-label use is not FDA-approved.
Oral
Oral Rapamycin (Low-Dose)
OralCompounded / individualizedA low-dose sirolimus protocol that may be discussed off-label for selected patients. This use is not FDA-approved for longevity or healthy aging.
How these options are considered
The goal here is clinician-guided review, not self-selection of a consumer anti-aging product. If a treatment is discussed, it is discussed alongside evidence limitations, monitoring needs, and regulatory status.
Evidence and regulatory disclosures
- Offerings in this category range from limited human studies to early-stage research, depending on the product.
- Some anti-aging offerings involve compounded medications that are not FDA-approved, and some uses may be prescribed off-label at a clinician's discretion.